TP53 and cancer: In particular, R181L was among the first p53 cancer mutants reported to be specifically deficient for binding and activating pro‐apoptotic target genes while retaining regulation of other genes such as CDKN1A and MDM2 (Ludwig et al, 1996; Schlereth et al, 2010a).